A six‑month competition called the “Younger contest” challenges participants to lower their biological age, as measured by a suite of aging‑clock tools, by submitting blood‑spot samples, cognitive test results, grip‑strength data and facial‑photo analyses. The contest, created by neuroscientist and physician Christin Glorioso, founder and CEO of NeuroAge Therapeutics, features a public leaderboard that ranks competitors by the gap between chronological and biological age and by the amount of age reversal achieved.
Key Takeaways
- The Younger contest runs for six months and measures reversal of biological age across multiple organ systems.
- Participants provide blood‑spot, cognitive, grip‑strength and facial‑photo data to generate organ‑specific and overall age scores.
- TruDiagnostic supplies epigenetic DNA‑based age metrics for eleven organ systems, while NeuroAge Therapeutics contributes brain‑health tracking and an Alzheimer’s‑risk trial.
- A public leaderboard displays both chronological‑biological age gaps and total age‑reversal amounts.
| Metric | Value | Why it matters |
|---|---|---|
| Contest duration | Six months | Sets a finite window for measurable age‑reversal outcomes. |
| Creator | Christin Glorioso | Neuroscientist‑physician leading the contest design. |
| Primary age‑clock provider | TruDiagnostic | Delivers epigenetic DNA measurements for overall and organ‑specific ages. |
| Brain‑health partner | NeuroAge Therapeutics | Runs a trial on biological brain age and Alzheimer’s risk. |
What the Younger Contest Measures
The competition aggregates four distinct data streams: a dried‑blood‑spot assay, a standardized cognitive test, a grip‑strength measurement and a facial‑photo analysis. Each input feeds into proprietary algorithms that output both organ‑specific ages—covering eleven systems according to TruDiagnostic’s epigenetic clock—and a composite biological‑age score.
Technology Behind the Age Clocks
TruDiagnostic’s platform quantifies epigenetic chemical groups attached to DNA, a biomarker that correlates with cellular aging. By mapping these modifications across eleven organ systems, the service can report a “pace‑of‑aging” metric alongside absolute age estimates. NeuroAge Therapeutics contributes brain‑focused analytics, leveraging its own tracking tools to assess neural health and estimate a biological brain age that ties into Alzheimer’s‑risk modeling.
Participant Workflow and Data Submission
Entrants receive a kit for collecting a finger‑prick blood spot, which they mail back for epigenetic analysis. Cognitive performance is captured via an online test administered by the Harvard‑affiliated app team, while grip strength is measured with a standard dynamometer. A high‑resolution facial photograph is uploaded through the same app, enabling computer‑vision assessment of skin texture and facial morphology. The aggregated results generate a personalized dashboard that displays organ‑specific ages, overall biological age and the delta from the participant’s chronological age.
Leaderboard Mechanics
The public leaderboard ranks competitors on two axes: the numerical gap between chronological and biological age, and the total amount of biological‑age reversal recorded over the competition period. This dual‑ranking system incentivizes both a low baseline biological age and demonstrable improvement, creating a dynamic where participants can chase either a “youngest‑biological‑age” title or the greatest “age‑reversal” score.
Why It Matters
By coupling epigenetic profiling with functional assessments (cognition, strength, facial analysis), the Younger contest offers a rare, real‑world testbed for multi‑modal age‑reversal strategies. The public leaderboard adds transparency and competitive pressure, potentially accelerating adoption of interventions that demonstrably shift biological age. Moreover, NeuroAge Therapeutics’ parallel brain‑age trial could surface early signals linking systemic age‑reversal to reduced Alzheimer’s risk, a connection of high clinical interest.
Frequently asked questions
Who created the Younger contest?
The contest was created by Christin Glorioso, a neuroscientist and physician who is also the founder and CEO of NeuroAge Therapeutics.
What types of data are required from participants?
Participants must submit a dried‑blood‑spot sample, results from a cognitive test, grip‑strength measurements and a facial photograph for analysis.
Which companies provide the age‑measurement technology?
TruDiagnostic supplies the epigenetic DNA‑based overall and organ‑specific age metrics, while NeuroAge Therapeutics contributes brain‑health tracking tools and runs a related trial on biological brain age.
How are competitors ranked?
The public leaderboard ranks entrants by the gap between their chronological and biological ages and by the total amount of biological‑age reversal achieved during the six‑month period.
Is there an academic partner involved?
A Harvard‑affiliated app team provides the platform for cognitive testing and data submission.
Bottom Line
The Younger contest merges epigenetic, functional and visual biomarkers into a six‑month competitive framework, offering a transparent arena for testing age‑reversal interventions. Led by Christin Glorioso and supported by TruDiagnostic and NeuroAge Therapeutics, the contest’s public leaderboard and multi‑organ age metrics could shape future research on systemic aging and neurodegenerative risk.
Reporting based on: original source.
Comments
Post a Comment